Operating Income Summary of ResMed Inc.

ResMed Inc.'s latest annual operating income in 2024 was 1.31 Billion USD , up 16.61% from previous year.
ResMed Inc.'s latest quarterly operating income in 2024 FY was 1.38 Billion USD , up 22.29% from previous quarter.
ResMed Inc. reported an annual operating income of 1.13 Billion USD in 2023, up 13.15% from previous year.
ResMed Inc. reported an annual operating income of 1 Billion USD in 2022, up 10.69% from previous year.
ResMed Inc. reported a quarterly operating income of 381.21 Million USD for 2024 Q4, up 1.77% from previous quarter.
ResMed Inc. reported a quarterly operating income of 1.38 Billion USD for 2024 FY, up 22.29% from previous quarter.

Annual Operating Income Chart of ResMed Inc. (2024 - 1993)

Historical Annual Operating Income of ResMed Inc. (2024 - 1993)

Year	Operating Income	Operating Income Growth
2024	1.31 Billion USD	16.61%
2023	1.13 Billion USD	13.15%
2022	1 Billion USD	10.69%
2021	903.67 Million USD	11.61%
2020	809.65 Million USD	39.77%
2019	579.26 Million USD	6.91%
2018	541.83 Million USD	27.25%
2017	425.79 Million USD	-0.74%
2016	428.95 Million USD	4.82%
2015	409.23 Million USD	1.02%
2014	405.08 Million USD	14.17%
2013	354.82 Million USD	20.52%
2012	294.4 Million USD	10.3%
2011	266.92 Million USD	11.04%
2010	240.38 Million USD	26.31%
2009	190.31 Million USD	33.11%
2008	142.97 Million USD	58.57%
2007	90.16 Million USD	-31.33%
2006	131.3 Million USD	34.87%
2005	97.35 Million USD	14.05%
2004	85.36 Million USD	26.95%
2003	67.24 Million USD	231.43%
2002	-51.15 Million USD	-296.45%
2001	26.04 Million USD	-21.41%
2000	33.13 Million USD	30.98%
1999	25.3 Million USD	46.24%
1998	17.3 Million USD	108.43%
1997	8.3 Million USD	124.32%
1996	3.7 Million USD	32.14%
1995	2.8 Million USD	115.38%
1994	1.3 Million USD	85.71%
1993	700 Thousand USD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q2	275.09 Million USD	-4.81%
2024 Q4	381.21 Million USD	1.77%
2024 FY	1.38 Billion USD	22.29%
2024 Q3	374.58 Million USD	36.17%
2024 Q1	288.99 Million USD	4.99%
2023 FY	1.13 Billion USD	13.15%
2023 Q3	300.67 Million USD	7.31%
2023 Q4	275.26 Million USD	-8.45%
2023 Q2	280.19 Million USD	1.62%
2023 Q1	275.73 Million USD	7.97%
2022 Q1	261.91 Million USD	8.39%
2022 Q3	234.26 Million USD	-5.81%
2022 FY	1 Billion USD	10.69%
2022 Q4	255.39 Million USD	9.02%
2022 Q2	248.71 Million USD	-5.04%
2021 FY	903.67 Million USD	11.61%
2021 Q4	241.63 Million USD	8.15%
2021 Q2	221.71 Million USD	2.22%
2021 Q1	216.89 Million USD	-2.84%
2021 Q3	223.42 Million USD	0.77%
2020 Q3	217.5 Million USD	9.95%
2020 FY	809.65 Million USD	39.77%
2020 Q4	223.24 Million USD	2.64%
2020 Q1	171.1 Million USD	41.32%
2020 Q2	197.8 Million USD	15.61%
2019 Q2	157.07 Million USD	8.98%
2019 FY	579.26 Million USD	6.91%
2019 Q4	121.07 Million USD	-22.87%
2019 Q1	144.13 Million USD	-1.87%
2019 Q3	156.97 Million USD	-0.06%
2018 Q4	146.88 Million USD	7.71%
2018 FY	541.83 Million USD	27.25%
2018 Q3	136.37 Million USD	-6.6%
2018 Q2	146.01 Million USD	29.73%
2018 Q1	112.55 Million USD	-11.62%
2017 Q2	96.89 Million USD	2.92%
2017 Q3	107.39 Million USD	10.84%
2017 FY	425.79 Million USD	-0.74%
2017 Q4	127.36 Million USD	18.59%
2017 Q1	94.14 Million USD	-20.64%
2016 Q2	107.97 Million USD	10.15%
2016 FY	428.95 Million USD	4.82%
2016 Q3	104.31 Million USD	-3.39%
2016 Q4	118.63 Million USD	13.73%
2016 Q1	98.02 Million USD	-1.53%
2015 Q4	99.54 Million USD	-5.97%
2015 Q3	105.86 Million USD	-3.0%
2015 Q1	94.67 Million USD	-3.87%
2015 FY	409.23 Million USD	1.02%
2015 Q2	109.14 Million USD	15.28%
2014 FY	405.08 Million USD	14.17%
2014 Q4	98.48 Million USD	-5.93%
2014 Q1	96.88 Million USD	12.44%
2014 Q2	105.02 Million USD	8.4%
2014 Q3	104.69 Million USD	-0.31%
2013 FY	354.82 Million USD	20.52%
2013 Q1	80.48 Million USD	-10.3%
2013 Q2	92.07 Million USD	14.39%
2013 Q4	86.16 Million USD	-10.34%
2013 Q3	96.09 Million USD	4.38%
2012 Q3	76.54 Million USD	13.82%
2012 FY	294.4 Million USD	10.3%
2012 Q1	60.87 Million USD	-8.73%
2012 Q2	67.25 Million USD	10.48%
2012 Q4	89.73 Million USD	17.22%
2011 Q2	69.87 Million USD	5.24%
2011 Q3	200.22 Million USD	186.56%
2011 Q4	66.69 Million USD	-66.69%
2011 FY	266.92 Million USD	11.04%
2011 Q1	66.39 Million USD	-3.24%
2010 FY	240.38 Million USD	26.31%
2010 Q1	52.66 Million USD	-9.04%
2010 Q2	57.92 Million USD	9.99%
2010 Q3	61.17 Million USD	5.62%
2010 Q4	68.61 Million USD	12.16%
2009 Q3	52.51 Million USD	21.2%
2009 Q2	43.33 Million USD	18.5%
2009 Q4	57.89 Million USD	10.25%
2009 Q1	36.56 Million USD	-1.14%
2009 FY	190.31 Million USD	33.11%
2008 Q1	31.76 Million USD	-11.88%
2008 FY	142.97 Million USD	58.57%
2008 Q4	36.98 Million USD	-1.08%
2008 Q3	37.38 Million USD	1.51%
2008 Q2	36.83 Million USD	15.96%
2007 Q1	35.31 Million USD	-6.49%
2007 Q2	40.69 Million USD	15.22%
2007 FY	90.16 Million USD	-31.33%
2007 Q4	36.04 Million USD	264.66%
2007 Q3	-21.89 Million USD	-153.8%
2006 Q3	36.74 Million USD	13.85%
2006 Q4	37.76 Million USD	2.78%
2006 Q2	32.27 Million USD	31.67%
2006 Q1	24.51 Million USD	3.18%
2006 FY	131.3 Million USD	34.87%
2005 Q2	25.6 Million USD	22.18%
2005 Q1	20.96 Million USD	-14.53%
2005 FY	97.35 Million USD	14.05%
2005 Q4	23.75 Million USD	-12.1%
2005 Q3	27.02 Million USD	5.54%
2004 Q1	18.95 Million USD	2.17%
2004 Q2	19.39 Million USD	2.32%
2004 FY	85.36 Million USD	26.95%
2004 Q4	24.52 Million USD	9.03%
2004 Q3	22.49 Million USD	15.97%
2003 Q2	16.07 Million USD	3.62%
2003 Q3	17.1 Million USD	6.43%
2003 Q4	18.55 Million USD	8.45%
2003 FY	67.24 Million USD	231.43%
2003 Q1	15.51 Million USD	117.17%
2002 FY	-51.15 Million USD	-296.45%
2002 Q3	12.57 Million USD	-6.51%
2002 Q1	13.18 Million USD	-0.03%
2002 Q2	13.44 Million USD	1.96%
2002 Q4	-90.36 Million USD	-818.82%
2001 Q4	13.19 Million USD	318.11%
2001 FY	26.04 Million USD	-21.41%
2001 Q3	-6.04 Million USD	-161.76%
2001 Q2	9.79 Million USD	7.52%
2001 Q1	9.1 Million USD	2.38%
2000 Q2	8.5 Million USD	14.86%
2000 Q3	8.25 Million USD	-2.86%
2000 Q4	8.89 Million USD	7.73%
2000 FY	33.13 Million USD	30.98%
2000 Q1	7.4 Million USD	2.78%
1999 Q1	5.3 Million USD	-5.36%
1999 Q2	6 Million USD	13.21%
1999 Q3	6.8 Million USD	13.33%
1999 Q4	7.2 Million USD	5.88%
1999 FY	25.3 Million USD	46.24%
1998 Q1	2.6 Million USD	0.0%
1998 Q3	4.4 Million USD	-6.38%
1998 Q4	5.6 Million USD	27.27%
1998 FY	17.3 Million USD	108.43%
1998 Q2	4.7 Million USD	80.77%
1997 FY	8.3 Million USD	124.32%
1997 Q3	2.2 Million USD	15.79%
1997 Q4	2.6 Million USD	18.18%
1997 Q1	1.5 Million USD	25.0%
1997 Q2	1.9 Million USD	26.67%
1996 FY	3.7 Million USD	32.14%
1996 Q3	1.1 Million USD	-86.08%
1996 Q4	1.2 Million USD	9.09%
1996 Q1	6.7 Million USD	147.86%
1996 Q2	7.9 Million USD	17.91%
1995 Q2	5.6 Million USD	0.0%
1995 Q3	5.6 Million USD	0.0%
1995 FY	2.8 Million USD	115.38%
1995 Q4	-14 Million USD	-350.0%
1995 Q1	5.6 Million USD	160.87%
1994 Q4	-9.2 Million USD	-362.86%
1994 FY	1.3 Million USD	85.71%
1994 Q1	3.5 Million USD	170.0%
1994 Q3	3.5 Million USD	0.0%
1994 Q2	3.5 Million USD	0.0%
1993 Q2	1.9 Million USD	0.0%
1993 FY	700 Thousand USD	0.0%
1993 Q3	1.9 Million USD	0.0%
1993 Q1	1.9 Million USD	0.0%
1993 Q4	-5 Million USD	-363.16%

Peer Operating Income Comparison of ResMed Inc.

Name	Operating Income	Operating Income Difference
Alcon Inc.	1.03 Billion USD	-27.035%
AptarGroup, Inc.	404.01 Million USD	-226.691%
Baxter International Inc.	390 Million USD	-238.434%
Becton, Dickinson and Company	2.42 Billion USD	45.571%
Bausch + Lomb Corporation	130 Million USD	-915.302%
Haemonetics Corporation	164.88 Million USD	-700.503%
Envista Holdings Corp	31.5 Million USD	-4090.137%
Teleflex Incorporated	506.31 Million USD	-160.687%
Warby Parker Inc.	-71.99 Million USD	1933.287%
West Pharmaceutical Services, Inc.	676 Million USD	-95.25%

Global Stocks Search

ResMed Inc. (RMD)

Operating Income Summary of ResMed Inc.

Annual Operating Income Chart of ResMed Inc. (2024 - 1993)

Historical Annual Operating Income of ResMed Inc. (2024 - 1993)

Peer Operating Income Comparison of ResMed Inc.